Blood
Articles in this Issue
Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma
Abstract Introduction: Relapsed and refractory classic Hodgkin lymphoma (cHL) is typically treated with salvage chemotherapy, followed by hi...
Searching for a myelodysplastic syndrome stem cells (MDS-SCs) signature by flow cytometry: Toward a new prognostic tool?
Abstract Introduction Myelodysplastic Syndromes (MDS) are a group of clonal myeloid disorders characterized by poor prog...
Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia
Abstract Background: While the overall survival for patients with chronic myeloid leukemia (CML) has improved significantly after the introd...
Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia
Abstract Background Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM), characterized by the pres...
Longterm outcome of patients with clonal cytopenia of undetermined significance: 10 year follow-up of a large unselected cohort
Abstract Introduction The long-term outcome of patients with clonal cytopenia of undetermined significance (CCUS) remain...
CD39 defines an exhausted effector memory T cell subset associated with poor outcome in Acute Myeloid Leukemia: Immunophenotypic and transcriptomic analysis
Abstract Recent advances in cancer immunology have highlighted the role of T cell exhaustion and immune checkpoint pathways in shaping the t...
Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries
Abstract IntroductionThe treatment landscape of early relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has been transformed by anti-CD...
Trends in outcomes and hospitalization of patients with multiple myeloma and hip fractures: An analysis of the national inpatient sample (2016 - 2021)
Abstract Background: Multiple myeloma (MM) accounts for approximately 10% of hematologic malignancies in the United Stat...
Dissecting the whole trajectory of aid-induced genomic instability from mutational activity to chromosomal translocation formation
Abstract Chromosomal translocations are key genomic events that frequently occur in hematopoietic cancers and solid tumors. In lymphoma and...
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.
Abstract Introduction The permanent discontinuation of treatments with tyrosine kinase inhibitors (TKIs) (treatment-free...
Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study
Abstract Introduction We conducted a multinational, multicenter prospective registry study to better define the treatment patterns and survi...
Missense mutations in the PWWP domain of DNMT3A can cause cytoplasmic mislocalization of DNMT3A in AML cells
Abstract DNMT3A is a de novo DNA methyltransferase that is highly expressed in hematopoietic stem/progenitor cells. Mutations in this gene a...
Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma
Abstract Introduction Despite the development of potent therapeutics, multiple myeloma (MM) remains an incurable disease...
A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome
Abstract Background: The prognosis for patients (pts) with advanced-stage Mycosis Fungoides (MF) and Sézary syndrome (SS) is poor and more e...
Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)
Abstract Background: Bruton tyrosine kinase (BTK) inhibitors are a standard of care in CLL. Zanubrutinib, a next-generation BTK inhibitor, w...
Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways
Abstract Background: Quizartinib, a FLT3 inhibitor, has been shown to induce quiescence in healthy hematopoietic stem and progenitor cells (H...
Adherence to oral iron in adolescent females with iron deficiency secondary to heavy menstrual bleeding
Abstract Background: Iron deficiency (ID) is an important, but minimized, health issue among adolescent females in the US. ID is the known p...
Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma
Abstract Background: Talquetamab (Talq), a GPRC5D-targeted bispecific antibody (BsAb), has demonstrated efficacy in clinical trials for relap...
Being an adult with shwachman diamond syndrome- an analysis of 36 german patients registered in the severe chronic neutropenia international registry/SDS-registry europe
Abstract Background Shwachman-Diamond Syndrome (SDS) is a multisystem disorder characterized by exocrine pancreatic insufficiency and bone m...
Risk stratification of newly diagnosed AML receiving nonintensive treatment
Abstract Background: Risk stratification is essential in guiding treatment decisions in acute myeloid leukemia (AML). While the European Leu...
Smoking and chronic kidney disease are associated with expansion of TET2 clonal hematopoiesis of indeterminate potential (CHIP)
Abstract Background CHIP is linked to blood cancer risk and adverse non-haematological health outcomes, with variant allele frequency (VAF)...
Real-world AML survival paradox: Early escalation vs. sustained remission
Abstract The prognostic value of measurable residual disease (MRD) is well established in acute myeloid leukemia (AML), with strong evidence...
Comparable outcomes after autologous hematopoietic cell transplantation in T-cell lymphoma regardless of pre-transplant response: A key finding in resource-limited countries.
Abstract Introduction. T-cell lymphomas represent about 10% of non-Hodgkin lymphomas (NHL), are a rare type and the inci...
HMGA1 chromatin regulator induces inflammatory signals and promotes atherogenesis in Tet2 mutant clonal hematopoiesis
Abstract Introduction: Clonal hematopoiesis (CH) is common with aging and associated with an increased risk for atherosclerosis (AS) and othe...
Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.
Abstract Introduction: Doublet maintenance regimens of lenalidomide and CD38 MoAb may facilitate the eradication of MM cells, especially in...